Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer

A Retrospective Review of Disease Presentation, Treatment, and Outcomes

Darrin V. Bann, Irina Chaikhoutdinov, Junjia Zhu, Genevieve Andrews

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Satellitosis and in-transit metastases (SITM) are uncommon in cutaneous melanoma and are associated with poor prognosis. However, the disease- and treatment-specific variables that predict outcomes among patients with SITM are poorly defined. OBJECTIVE: To identify factors that predict prognosis among patients with SITM. MATERIALS AND METHODS: Retrospective chart review of patients treated for melanoma at a large academic medical center in central Pennsylvania between 2000 and 2012. Patients with pathology reports containing "satellite lesions" or "in-transit metastases" were selected for analysis. Data were collected regarding tumor stage, the timing of SITM discovery, treatment, recurrence-free survival after SITM discovery, and overall survival (OS). RESULTS: We identified SITM in 32 (1.9%) of 1,650 patients with pathology-diagnosed melanoma over the study period. Reduced recurrence-free survival after SITM discovery was associated with higher pathologic stage, metastatic disease, lymph node dissection, and use of adjuvant chemotherapy. Reduced OS was associated with higher T, N, M, and overall prognostic stage; positive surgical margins; disease recurrence; and SITM on initial presentation. CONCLUSION: Our data support previous findings that higher stage disease confers a worse prognosis among patients with SITM. Patients with SITM on initial presentation had worse outcomes, suggesting SITM is indicative of more aggressive disease.

Original languageEnglish (US)
Pages (from-to)371-380
Number of pages10
JournalDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Volume45
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Skin Neoplasms
Melanoma
Neoplasm Metastasis
Survival
Recurrence
Pathology
Adjuvant Chemotherapy
Lymph Node Excision

All Science Journal Classification (ASJC) codes

  • Surgery
  • Dermatology

Cite this

@article{ab701cb91c5e4eca9a52b1ed7d14a8ba,
title = "Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes",
abstract = "BACKGROUND: Satellitosis and in-transit metastases (SITM) are uncommon in cutaneous melanoma and are associated with poor prognosis. However, the disease- and treatment-specific variables that predict outcomes among patients with SITM are poorly defined. OBJECTIVE: To identify factors that predict prognosis among patients with SITM. MATERIALS AND METHODS: Retrospective chart review of patients treated for melanoma at a large academic medical center in central Pennsylvania between 2000 and 2012. Patients with pathology reports containing {"}satellite lesions{"} or {"}in-transit metastases{"} were selected for analysis. Data were collected regarding tumor stage, the timing of SITM discovery, treatment, recurrence-free survival after SITM discovery, and overall survival (OS). RESULTS: We identified SITM in 32 (1.9{\%}) of 1,650 patients with pathology-diagnosed melanoma over the study period. Reduced recurrence-free survival after SITM discovery was associated with higher pathologic stage, metastatic disease, lymph node dissection, and use of adjuvant chemotherapy. Reduced OS was associated with higher T, N, M, and overall prognostic stage; positive surgical margins; disease recurrence; and SITM on initial presentation. CONCLUSION: Our data support previous findings that higher stage disease confers a worse prognosis among patients with SITM. Patients with SITM on initial presentation had worse outcomes, suggesting SITM is indicative of more aggressive disease.",
author = "Bann, {Darrin V.} and Irina Chaikhoutdinov and Junjia Zhu and Genevieve Andrews",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/DSS.0000000000001643",
language = "English (US)",
volume = "45",
pages = "371--380",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer

T2 - A Retrospective Review of Disease Presentation, Treatment, and Outcomes

AU - Bann, Darrin V.

AU - Chaikhoutdinov, Irina

AU - Zhu, Junjia

AU - Andrews, Genevieve

PY - 2019/3/1

Y1 - 2019/3/1

N2 - BACKGROUND: Satellitosis and in-transit metastases (SITM) are uncommon in cutaneous melanoma and are associated with poor prognosis. However, the disease- and treatment-specific variables that predict outcomes among patients with SITM are poorly defined. OBJECTIVE: To identify factors that predict prognosis among patients with SITM. MATERIALS AND METHODS: Retrospective chart review of patients treated for melanoma at a large academic medical center in central Pennsylvania between 2000 and 2012. Patients with pathology reports containing "satellite lesions" or "in-transit metastases" were selected for analysis. Data were collected regarding tumor stage, the timing of SITM discovery, treatment, recurrence-free survival after SITM discovery, and overall survival (OS). RESULTS: We identified SITM in 32 (1.9%) of 1,650 patients with pathology-diagnosed melanoma over the study period. Reduced recurrence-free survival after SITM discovery was associated with higher pathologic stage, metastatic disease, lymph node dissection, and use of adjuvant chemotherapy. Reduced OS was associated with higher T, N, M, and overall prognostic stage; positive surgical margins; disease recurrence; and SITM on initial presentation. CONCLUSION: Our data support previous findings that higher stage disease confers a worse prognosis among patients with SITM. Patients with SITM on initial presentation had worse outcomes, suggesting SITM is indicative of more aggressive disease.

AB - BACKGROUND: Satellitosis and in-transit metastases (SITM) are uncommon in cutaneous melanoma and are associated with poor prognosis. However, the disease- and treatment-specific variables that predict outcomes among patients with SITM are poorly defined. OBJECTIVE: To identify factors that predict prognosis among patients with SITM. MATERIALS AND METHODS: Retrospective chart review of patients treated for melanoma at a large academic medical center in central Pennsylvania between 2000 and 2012. Patients with pathology reports containing "satellite lesions" or "in-transit metastases" were selected for analysis. Data were collected regarding tumor stage, the timing of SITM discovery, treatment, recurrence-free survival after SITM discovery, and overall survival (OS). RESULTS: We identified SITM in 32 (1.9%) of 1,650 patients with pathology-diagnosed melanoma over the study period. Reduced recurrence-free survival after SITM discovery was associated with higher pathologic stage, metastatic disease, lymph node dissection, and use of adjuvant chemotherapy. Reduced OS was associated with higher T, N, M, and overall prognostic stage; positive surgical margins; disease recurrence; and SITM on initial presentation. CONCLUSION: Our data support previous findings that higher stage disease confers a worse prognosis among patients with SITM. Patients with SITM on initial presentation had worse outcomes, suggesting SITM is indicative of more aggressive disease.

UR - http://www.scopus.com/inward/record.url?scp=85062721194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062721194&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000001643

DO - 10.1097/DSS.0000000000001643

M3 - Article

VL - 45

SP - 371

EP - 380

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 3

ER -